ZTS has been the topic of several other research reports. Bank of America Corp. started coverage on shares of Zoetis in a report on Thursday, September 29th. They issued a buy rating and a $60.00 target price on the stock. Zacks Investment Research cut shares of Zoetis from a hold rating to a sell rating in a report on Thursday. Guggenheim restated a positive rating and issued a $60.00 target price on shares of Zoetis in a report on Monday, August 22nd. Citigroup Inc. raised their target price on shares of Zoetis from $50.00 to $53.00 and gave the stock a neutral rating in a report on Thursday, August 4th. Finally, Stifel Nicolaus restated a buy rating and issued a $58.00 target price on shares of Zoetis in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Zoetis currently has an average rating of Buy and a consensus price target of $55.50.
Shares of Zoetis (NYSE:ZTS) opened at 50.18 on Friday. The firm’s 50-day moving average is $51.25 and its 200-day moving average is $49.01. Zoetis has a 52 week low of $38.26 and a 52 week high of $53.14. The company has a market cap of $24.84 billion, a price-to-earnings ratio of 39.08 and a beta of 1.01.
Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the business earned $0.43 earnings per share. The business’s revenue was up 2.8% on a year-over-year basis. Equities research analysts predict that Zoetis will post $1.91 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be given a $0.095 dividend. This represents a $0.38 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Tuesday, November 1st. Zoetis’s dividend payout ratio is presently 29.69%.
In related news, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $51.25, for a total value of $710,837.50. Following the completion of the sale, the insider now directly owns 17,719 shares in the company, valued at approximately $908,098.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael B. Mccallister acquired 2,000 shares of Zoetis stock in a transaction that occurred on Tuesday, September 6th. The stock was acquired at an average price of $51.34 per share, with a total value of $102,680.00. The disclosure for this purchase can be found here. 0.05% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC increased its stake in Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock valued at $319,000 after buying an additional 26 shares during the last quarter. Sterneck Capital Management LLC increased its stake in Zoetis by 0.7% in the second quarter. Sterneck Capital Management LLC now owns 5,766 shares of the company’s stock valued at $274,000 after buying an additional 38 shares during the last quarter. Kistler Tiffany Companies LLC increased its stake in Zoetis by 1.1% in the second quarter. Kistler Tiffany Companies LLC now owns 6,231 shares of the company’s stock valued at $296,000 after buying an additional 65 shares during the last quarter. Fulton Bank N.A. increased its stake in Zoetis by 1.6% in the third quarter. Fulton Bank N.A. now owns 5,279 shares of the company’s stock valued at $275,000 after buying an additional 83 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in Zoetis by 1.9% in the first quarter. Jones Financial Companies Lllp now owns 6,039 shares of the company’s stock valued at $268,000 after buying an additional 114 shares during the last quarter. Institutional investors own 93.12% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.